Stage III NSCLC Lung Cancer

Discover how Stage III NSCLC Lung Cancer affects the lungs and body. Learn about stages of lung cancer, how cancer spreads to nearby lymph nodes, how doctors diagnose the condition, what treatments work best, and what to expect after treatment.

Stage III represents a locally advanced stage, where the tumor grows larger and reaches structures inside the chest. It often spreads to nearby lymph nodes but has not yet moved to distant organs. Understanding how the stages of lung cancer progress helps patients make informed decisions and follow treatment plans that improve their outcomes.

What Is Stage III NSCLC Lung Cancer?

Stage III NSCLC Lung Cancer stands for non‑small cell lung cancer that has grown beyond early stages. Now, the tumor moves into the chest area. It affects nearby lymph nodes or even the chest wall and lung lining. The tumor meets the criteria for Stage IIIB or Stage IIIA. Doctors use CT scans to confirm how far cancer has grown into lung tissues and other parts of the body. This stage lies between early stage disease and metastasis.

How Cancer Spreads and What That Means

Lung cancer splits into two main types: small cell lung cancer and non-small cell lung cancer (NSCLC).

Stage IIIA vs Stage IIIB Spread

Patients reach Stage IIIA lung cancer when cancer cells spread to mediastinal lymph nodes on the same side as the tumor. Once cancer expands into lymph nodes on the other side or invades the chest wall, it becomes Stage IIIB. At this point, cancer still stays inside the chest but becomes locally advanced.

How Cancer Cells Travel

Cancer cells invade the layer of the colon of lung airways and make their way into nearby lymph nodes. They move into nearby organs and chest structures. However, these cells don’t yet travel to distant organs such as the liver or brain. Therefore, cancer hasn’t spread too far.

Survival Rates and Options

Statistics show survival rates differ for each substage. In Stage IIIA, five‑year survival sits between 36% and 55%. In Stage IIIB, it drops to roughly 20‑36%. Despite this, modern treatments for stage III offer hope. Oncologists tailor plans that include radiation therapy, chemo, and immune system–boosting medicine. They adjust each plan based on tumor size, lymph node spread, and how many cancer cells remain after treatment begins.

Key Signs and Diagnosis

Symptoms

When cancer grows in the chest, people may notice chest pain, cough, shortness of breath, or weight loss. These symptoms appear once the tumor reaches the chest wall or lymph node area. Still, some patients remain symptom-free until doctors detect changes.

Imaging and Tissue Testing

Doctors use computed tomography CT to view tumor size and lymph node spread. They may also order PET scans. Then, they biopsy tissue to learn what type of cancer cells they face, often NSCLC. This step confirms that cancer has spread just to nearby tissues—no distant organs show signs yet.

Staging Patterns

Oncologists apply the TNM system to name stages like stage IIIA or stage IIIB. That indicates whether cancer has breached the lung wall, invaded nearby lymph nodes, or affected other chest structures. This staging system sets the right path for treatment options.

Treatment for Stage III NSCLC

A. Surgical Removal

When tumors appear in stage IIIA, doctors may remove the tumor and affected lymph nodes using minimally invasive surgery. In both IIIA and IIIB, surgery aims to achieve clear margins and keep lung function intact.

B. Radiation Therapy

Many patients receive radiation therapy either before or after surgery. Radiotherapy shrinks tumors and tackles cancer cells in nearby tissues. Newer tools help focus energy and spare healthy lung parts.

C. Combined Oncology Treatment

After surgery or radiation, specialists often add chemotherapy and immune system–boosting drugs. These aim to destroy cancer cells left behind. For Stage IIIB, doctors may skip surgery and rely on chemo + radiation + immunotherapy alone.

FAQs About Stage III NSCLC Lung Cancer

What's the difference between Stage 1 and Stage 2 lung cancer?

Doctors identify Stage 1 lung cancer when the tumor remains inside the lung and has not reached the lymph nodes. It usually involves a single small tumor that does not affect surrounding structures. Most patients with Stage 1 receive surgery as the primary treatment option, often without additional therapies.

In contrast, Stage 2 lung cancer shows further spread. The cancer cells may reach nearby lymph nodes or the chest wall but remain within the lung area. This early stage often requires a combination of surgery and adjuvant chemotherapy or radiation therapy to ensure the cancer has not spread further. The main difference lies in lymph node involvement and the tumor’s ability to invade nearby tissues.

What is Stage III non-small cell lung cancer (NSCLC)?

Stage III NSCLC lung cancer describes a locally advanced disease. Doctors find that the tumor has grown into areas near the lung, such as the mediastinal lymph nodes, chest wall, or other structures inside the chest. However, the cancer has not spread to distant parts of the body like the brain, bones, or liver.

Doctors divide Stage III into Stage IIIA and Stage IIIB, depending on the tumor size, lymph node spread, and whether the cancer reaches other areas within the chest. Patients often need combined treatments, including radiation therapy, chemotherapy, and sometimes surgery, based on their overall health and tumor location.

What Is Stage III NSCLC Lung Cancer?

Stage III NSCLC lung cancer means the tumor has grown larger and has started to spread within the chest. It reaches nearby lymph nodes, the chest wall, or the area between the lungs known as the mediastinum. This stage does not involve distant organs, but the cancer becomes harder to treat because of its location and size.

Understanding the Stages Within Stage III

Doctors divide Stage III into two main groups: Stage IIIA and Stage IIIB. In Stage IIIA, the tumor may still be small enough for doctors to remove with surgery. In Stage IIIB, the cancer usually grows too close to important structures like major blood vessels or the windpipe, so surgery may not work. Instead, doctors use strong treatments like chemotherapy and radiation therapy together.

Why Early and Aggressive Treatment Matters

Since Stage III NSCLC lung cancer is locally advanced, treatment must happen quickly and follow a plan designed for each person. The goal is to stop the cancer from growing, prevent it from spreading farther, and improve survival chances.

Can Stage III NSCLC Lung Cancer Be Cured?

In some cases, Stage III NSCLC lung cancer can be cured, especially when the cancer stays in one area of the chest. Patients with Stage IIIA may get surgery after finishing chemotherapy and radiation therapy. This approach works best when doctors can safely remove the tumor and the affected lymph nodes.

Treatment Options Depend on Spread and Health

People with Stage IIIB often cannot go through surgery because the cancer touches or presses on vital parts of the chest. However, aggressive treatment using both radiation therapy and chemotherapy helps control the cancer. New treatments such as immunotherapy support the immune system and give more patients a chance for long-term survival.

Living Strong With a Long-Term Plan

Doctors watch patients closely, run regular scans, and adjust treatments based on how well the body responds. Many patients live for years after diagnosis, especially when they follow their treatment plan, avoid tobacco, and take good care of their health.

Moving Forward with Strength

Stage III NSCLC Lung Cancer challenges patients with its local spread to lymph nodes and chest wall. However, doctors use strong treatment strategies combining surgery, radiation therapy, chemo, and immunotherapy. Staying informed and acting quickly empowers patients to control cancer and improve their survival rate.

Your Journey

Start Your Recovery

Our dedicated Patient Navigator will assist you with appointment scheduling. Contact us at +6012-3993260 (Call or Whatsapp ).

First Consultation

On appointment day, bring along all the medical reports and your identity documents, ie. identity card or passport. Our team will help you organize the medical reports for our oncologist to review. Our oncologist will discuss the treatment plan with you. Tele-consult is available for overseas patients.

Treatment Day

Come to our center on an agreed date and time for the treatment. Our team will take good care of you. You will be discharged on the same day. Yes, you will get to go home after every treatment visit as no overnight admission is required.

Stay on Track

Our dedicated patient navigator will be following up with you post treatment to check on your condition, to ensure that you are doing well. You will receive a reminder message on your phone for the next appointment date.

Dr. Christina Ng Van Tze

Consultant Medical Oncologist
Medical Director
MBBS (Melb) FRACP (Aus)

Monday - Friday : 08:00 AM TO 06:00 PM

Saturday : 08:00 AM TO 02:00 PM

D. Joseph K. Joseph

Consultant Medical Oncologist
MBBCH, BAO (IRE) MRCP (UK)

Wednesday : 08:00 AM TO 12:00 PM

Friday : 08:00 AM TO 12:00 PM

Advocacy Programs

Dr. Christina Ng Represents Onco Life Centre at ESMO 2025

Hello, I’m Dr. Christina Ng Van Tze, a Consultant Medical Oncologist and Medical Director at Onco Life Centre, as well as the Founder President of Empowered The Cancer Advocacy Society of Malaysia. Throughout my career, I have been passionate about advancing personalized cancer treatment, strengthening community advocacy, and expanding access to high-quality care for patients across Malaysia.

Attending the ESMO Congress 2025 in Berlin was both inspiring and energizing. Representing Onco Life Centre, our dedicated medical centre in Malaysia, I stood among global leaders committed to shaping the future of oncology. This year’s congress was filled with remarkable scientific breakthroughs, thoughtful discussions, and a renewed sense of purpose as we work toward better outcomes and better lives for our patients.

A Global Gathering Focused on Precision Cancer Care

ESMO 2025 brought together thousands of clinicians, researchers, and advocates from around the world. What made this year particularly exciting was the strong emphasis on precision medicine, from cancer genetics and molecular profiling to advanced imaging and AI-powered diagnostic tools. These advancements are aligning closely with the work we do at Onco Life Centre, where patient individuality and tumor biology guide our treatment decisions.

Throughout the congress, many experts highlighted the importance of understanding each patient’s tumor in greater depth. Whether through genomic sequencing, circulating tumor DNA, or radiomic analyses, the oncology community is moving firmly toward personalized strategies. As someone who has long championed individualized care, I found these sessions especially meaningful.

Key Scientific Sessions That Inspired Me

One of the standout presentations was the evERA BC trial, a major study evaluating the combination of giredestrant, an oral SERD, with an mTOR inhibitor drug in hormone receptor-positive breast cancer. The results showed a significant improvement in progression-free survival, especially in tumors driven by ESR1 mutations. For patients who have progressed on CDK4/6 inhibitors, this combination may become an essential addition to our treatment toolbox.

This study also supports a larger movement within oncology—creating thoughtful, layered treatment plans that address resistance pathways and extend the time patients can remain on endocrine-based therapies. It’s a direction that can profoundly benefit Malaysian women, many of whom are diagnosed at younger ages or have aggressive tumor profiles.

Insights from the thoracic oncology sessions were equally impactful. Advances in lung cancer, including AI-driven pathology models, updated ALK-targeted treatment strategies, and ctDNA-guided therapy adjustments, reminded me just how quickly this field is evolving. Given the increasing prevalence of lung cancer in Malaysia, especially among non-smokers and women, these developments hold tremendous value for our community.

The Role of AI in Transforming Clinical Practice

One major theme across the congress was the integration of artificial intelligence into clinical decision-making. Researchers demonstrated how AI models can analyze pathology slides, radiology images, and genomic data to predict which patients are more likely to respond to immunotherapy or targeted treatment. These tools help us avoid ineffective therapies and guide patients toward options with the most tremendous potential.

At Onco Life Centre, we have been exploring the use of digital technologies to streamline assessments and enhance patient monitoring. Seeing the global oncology community embrace these tools assures me that we are moving in the right direction. I hope that AI will continue to improve early detection, refine treatment selection, and ultimately support better survival outcomes for Malaysian patients.

Representing Onco Life Centre on the International Stage

Representing Onco Life Centre at an event of this scale was a true honor. Our centre has always focused on delivering holistic, science-driven care, and it was wonderful to share our experiences with colleagues from around the world. I had meaningful conversations about challenges related to access to molecular testing globally, variability in treatment availability, and the need for stronger psycho-oncology support systems.

These interactions not only validated the work we do but also highlighted areas where we can continue to grow. Bringing international insights back to Malaysia ensures that our patients benefit from the same cutting-edge thinking shaping care in Europe, America, and beyond.

Bringing ESMO Insights Home to Malaysia

Returning from Berlin, I feel a renewed commitment to integrating the latest research into our daily practice. In the coming months, we aim to:

Enhance our use of molecular profiling for breast, lung, and gastrointestinal cancers
Expand ctDNA testing where appropriate to guide treatment decisions
Strengthen multidisciplinary discussions for complex cases
Continue investing in supportive care and psycho-oncology services
Provide patients and families with clearer, more personalized education about treatment choices

As a clinician, I believe that every advancement, no matter how technical, must ultimately translate into compassionate, human-centered care. This balance of science and empathy remains at the core of our mission.

A Future of Hope and Collaboration

ESMO 2025 reaffirmed what I’ve always believed: oncology is advancing rapidly, but meaningful progress relies on collaboration, continuous learning, and a deep commitment to patient care. I’m genuinely grateful for the opportunity to represent Onco Life Centre on this global platform. Being part of these critical conversations strengthens our mission to raise the standard of oncology in Malaysia. It ensures our patients benefit from the latest, most effective innovations in cancer care.

Moving forward, we will continue engaging with global partners, conducting meaningful advocacy through Empowered, and ensuring our patients receive the highest standard of personalized treatment.

Together, we can build a future where every individual facing cancer feels seen, supported, and empowered.

Onco Life Centre Wins 2025 Best Oncology Clinic in Malaysia

We are proud to share that Onco Life Centre has been named the Oncology Clinic and Treatment Centre of the Year in Malaysia at the GlobalHealth Asia-Pacific Awards 2025, held in Bangkok.

This prestigious recognition is a testament to our unwavering commitment to delivering personalized, compassionate, and cutting-edge cancer care to our patients. The award reflects not just our clinical excellence, but our dedication to safety, community outreach, and innovation in oncology services.

The GlobalHealth Asia-Pacific Awards celebrate leading healthcare institutions across the region. Winners are chosen based on a comprehensive evaluation of criteria such as:

Excellence and Innovation: Transforming healthcare delivery and patient outcomes through progressive medical practices.
Patient Safety: Upholding the highest standards to ensure safe, comfortable, and effective treatment environments.
Community Involvement: Actively engaging in public awareness, screening programs, and care for underprivileged communities.
Technology Adoption: Integrating advanced diagnostics, therapies, and digital tools to enhance every aspect of care.
Impact and Measurable Results: Demonstrating tangible improvements in cancer detection, treatment success, and patient well-being.
Adaptability and Preparedness: Being resilient and forward-thinking in the face of global health challenges.
Leadership and Vision: Cultivating a culture that prioritizes empathy, innovation, and ongoing education.

This award inspires us to continue raising the bar in oncology care—not only through medical advancements but by remaining deeply rooted in our advocacy mission: to serve, educate, and empower every cancer patient, especially those most in need.

We dedicate this achievement to our patients, survivors, caregivers, and the entire Onco Life Centre community. Your courage fuels our purpose. Together, we will continue the fight—because every life matters.